Peptides and Hypothyroidism: Thyroid Support Research

By the NorthPeptide Research Team  |  February 11, 2026

Understanding Hypothyroidism and Hashimoto’s

Hypothyroidism occurs when the thyroid gland fails to produce sufficient thyroid hormones — principally thyroxine (T4) and triiodothyronine (T3). These hormones regulate metabolism, energy production, temperature regulation, cognitive function, and numerous other physiological processes. Deficiency leads to fatigue, weight gain, cold intolerance, cognitive slowing, depression, and in severe cases myxoedema.

In developed countries, approximately 90% of hypothyroidism cases are caused by Hashimoto’s thyroiditis — an autoimmune condition in which the immune system produces antibodies against thyroid antigens (primarily thyroid peroxidase, TPO, and thyroglobulin, TgAb), causing progressive inflammatory destruction of thyroid tissue. This is the same autoimmune paradigm as Type 1 diabetes — immune-mediated organ destruction — which is why some of the same immunomodulatory research strategies are being explored.

Thymosin Alpha-1: Immune Regulation in Autoimmune Thyroid Disease

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide with established immunomodulatory properties. It promotes thymic T cell maturation, supports regulatory T cell (Treg) function, and modulates Th1/Th17 inflammatory responses — the same immune pathways dysregulated in Hashimoto’s thyroiditis.

In Hashimoto’s, autoreactive Th1 and Th17 cells drive the inflammatory attack on thyroid tissue, while Treg function is suppressed. Research has explored whether restoring Treg activity through immune modulators could slow the autoimmune progression — and Thymosin Alpha-1 has shown Treg-supporting properties in multiple autoimmune models. Direct studies in Hashimoto’s-specific models are limited, but the mechanistic rationale is strong. Thymosin Alpha-1 is already used clinically as an immune modulator in chronic HBV and HCV infection and some cancers — giving it a more established safety profile than most research peptides.

BPC-157: Anti-Inflammatory and Tissue-Protective Properties

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protective gastric protein. Its research profile includes anti-inflammatory effects, protection of endothelial function, angiogenesis promotion, and gut integrity support. Its relevance to hypothyroidism is indirect but mechanistically logical:

• Systemic anti-inflammatory activity: BPC-157 reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in multiple tissue models. In Hashimoto’s, the inflammatory environment drives progressive thyroid cell death — compounds that reduce systemic inflammation may theoretically slow this process.
• Endothelial and vascular effects: BPC-157 has been shown to protect vascular endothelium and promote angiogenesis. Thyroid tissue is highly vascular, and the inflammation in Hashimoto’s disrupts thyroid vasculature.
• Gut-thyroid connection: Emerging research suggests that gut permeability and microbiome dysbiosis may play a role in autoimmune thyroid disease. BPC-157’s gut-protective properties may have indirect relevance.

NAD+ and Mitochondrial Function in Thyroid Metabolism

Thyroid hormones are primary regulators of mitochondrial activity — they directly influence mitochondrial biogenesis, oxidative phosphorylation capacity, and cellular metabolic rate. Hypothyroidism leads to mitochondrial dysfunction: reduced energy production, increased reactive oxygen species (ROS), and impaired cellular repair. NAD+ is essential for mitochondrial function and is a cofactor for sirtuins that regulate mitochondrial biogenesis.

Research has explored whether restoring NAD+ levels (through NMN, NR, or direct NAD+) can partially compensate for the mitochondrial dysfunction associated with hypothyroidism — not by restoring thyroid hormone levels, but by improving cellular energy metabolism downstream. Animal studies in hypothyroid models have shown that mitochondrial support can partially reverse some metabolic consequences of thyroid hormone deficiency.

Limitations: The Challenge of Autoimmune Thyroid Research

Hypothyroidism research with peptides faces important limitations:

• In established Hashimoto’s with significant gland destruction, immunomodulation cannot restore already-destroyed tissue — it can only slow further destruction
• Most patients are well managed with levothyroxine replacement — the research question is whether peptides can reduce autoimmune progression, not replace thyroid hormone
• Hashimoto’s-specific peptide studies are rare; most relevant data comes from other autoimmune models
• TPO and TgAb antibody levels are used as markers of autoimmune activity — research would need to measure these to assess whether immune-targeting peptides are having any effect

The Selenium Connection

Selenium is the one micronutrient with strong clinical evidence in Hashimoto’s — selenium supplementation has been shown in randomised trials to reduce TPO antibody levels and improve quality of life. Some peptides involved in selenoprotein function or antioxidant pathways may be tangentially relevant, though no direct research exists linking specific research peptides to selenium-thyroid interactions.

References